UMIN-CTR Clinical Trial

Recruitment status Main results already published
Unique ID issued by UMIN UMIN000013694
Receipt No. R000015986
Scientific Title Individualized tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs
Date of disclosure of the study information 2014/04/11
Last modified on 2020/04/16 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Individualized tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs
Acronym Tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs
Scientific Title Individualized tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs
Scientific Title:Acronym Tacrolimus therapy for ulcerative colitis based on CYP3A5 SNPs
Region
Japan

Condition
Condition ulcerative colitis
Classification by specialty
Gastroenterology
Classification by malignancy Others
Genomic information YES

Objectives
Narrative objectives1 To evaluate the clinical usefulness of determining the initial dosage of tacrolimus based on the SNPs status of CYP3A5
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes efficacy on day 7
Key secondary outcomes blood concentration on day 3
time to reach the target concentration (10ng/ml)

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Historical
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Gene
Interventions/Control_1 determine CYP3A5 SNP status
increase the initial dosage of tacrolimus
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
18 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1. individuals brom whom written informed consent was obtained
2. >=18 years old
3. patients who are going to take tacrolimus
Key exclusion criteria 1. women who are pregnant, breastfeeding, or possible to be pregnant
2. individuals who are considered ineligible by the investigator
Target sample size 30

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Taku Kobayashi
Organization Kitasato University Kitasato Institute Hospital
Division name Center for Advanced IBD Research and Treatment
Zip code
Address 5-9-1 Shirokane, Minato-ku, Tokyo
TEL 03-3444-6161
Email kobataku@insti.kitasato-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Taku Kobayashi
Organization Kitasato University Kitasato Institute Hospital
Division name Center for Advanced IBD Research and Treatment
Zip code
Address 5-9-1 Shirokane, Minato-ku, Tokyo
TEL 03-3444-6161
Homepage URL
Email kobataku@insti.kitasato-u.ac.jp

Sponsor
Institute Kitasato University Kitasato Institute Hospital
Institute
Department

Funding Source
Organization Kitasato University Kitasato Institute Hospital
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2014 Year 04 Month 11 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Main results already published
Date of protocol fixation
2014 Year 04 Month 20 Day
Date of IRB
2014 Year 05 Month 13 Day
Anticipated trial start date
2014 Year 05 Month 13 Day
Last follow-up date
2021 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2014 Year 04 Month 11 Day
Last modified on
2020 Year 04 Month 16 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000015986